Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.

Cancer medicine - 1 Aug 2023

Hu Qingjiang, Oki Eiji, Yamada Teppei, Kashiwada Tomomi, Sonoda Hideto, Kataoka Masato, Kawanaka Hirofumi, Tsuji Yasushi, Makiyama Akitaka, Nakashima Yuichiro, Ota Mitsuhiko, Kimura Yasue, Yoshizumi Tomoharu

Abstract excerpt

BACKGROUND: We aimed to clarify the genomic characteristics of HER2-positive and negative gastric cancer cases that potentially affect tumor progression and treatment response in a prospective trial. METHODS: We collected 80 formalin-fixed paraffin-embedded (FFPE) samples (49 HER2+ and 31 HER2-) from gastric cancer patients who participated in the TROX-A1 trial (UMIN000036865). We queried a 435-gene panel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Copy Number Variations
Share to Gastric Cancer Management and Outcomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to HER2/EGFR in Cancer Research

Share to Mutation

Share to Receptor, ErbB-2

Share to Stomach Neoplasms

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 37325934
DOI: 10.1002/cam4.6269
PMCID: PMC10469643

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.PMID 37325934Read ↗

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysisSemantic proximity Read ↗

Molecular characteristics of gastric cancer with ERBB2 amplificationSemantic proximity Read ↗

The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.Semantic proximity Read ↗

Genomic correlations for clinical outcomes in HER2-positive advanced gastric cancers treated using trastuzumab-based therapySemantic proximity Read ↗

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity Read ↗

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read ↗

Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.Semantic proximity Read ↗

Personalized medicine in gastric cancer: Where are we and where are we going?Semantic proximity Read ↗

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Semantic proximity Read ↗

Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric CancerSemantic proximity Read ↗

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapiesSemantic proximity Read ↗

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.